WO2004014311A3 - Nogo receptor antagonists - Google Patents

Nogo receptor antagonists Download PDF

Info

Publication number
WO2004014311A3
WO2004014311A3 PCT/US2003/025004 US0325004W WO2004014311A3 WO 2004014311 A3 WO2004014311 A3 WO 2004014311A3 US 0325004 W US0325004 W US 0325004W WO 2004014311 A3 WO2004014311 A3 WO 2004014311A3
Authority
WO
WIPO (PCT)
Prior art keywords
nogo receptor
nogo
receptor antagonists
antigen
disclosed
Prior art date
Application number
PCT/US2003/025004
Other languages
French (fr)
Other versions
WO2004014311A2 (en
Inventor
Daniel H S Lee
R Blake Pepinsky
Weiwei Li
Sylvia A Rabacchi
Jane K Relton
Dane S Worley
Stephen M Strittmatter
Dinah Y W Sah
Original Assignee
Univ Yale
Biogen Idec Inc
Daniel H S Lee
R Blake Pepinsky
Weiwei Li
Sylvia A Rabacchi
Jane K Relton
Dane S Worley
Stephen M Strittmatter
Dinah Y W Sah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Biogen Idec Inc, Daniel H S Lee, R Blake Pepinsky, Weiwei Li, Sylvia A Rabacchi, Jane K Relton, Dane S Worley, Stephen M Strittmatter, Dinah Y W Sah filed Critical Univ Yale
Priority to BRPI0313331-1A priority Critical patent/BR0313331A/en
Priority to DK03785123.5T priority patent/DK1534736T3/en
Priority to EA200500330A priority patent/EA200500330A1/en
Priority to DE60332842T priority patent/DE60332842D1/en
Priority to SI200331860T priority patent/SI1534736T1/en
Priority to CA002495121A priority patent/CA2495121A1/en
Priority to EP03785123A priority patent/EP1534736B1/en
Priority to MXPA05001615A priority patent/MXPA05001615A/en
Priority to AU2003264033A priority patent/AU2003264033A1/en
Priority to YUP-2005/0129A priority patent/RS20050129A/en
Priority to AT03785123T priority patent/ATE469913T1/en
Priority to JP2004527960A priority patent/JP2005535329A/en
Priority to PCT/US2004/002702 priority patent/WO2005016955A2/en
Priority to CNA2004800294122A priority patent/CN1926147A/en
Priority to MXPA06001444A priority patent/MXPA06001444A/en
Priority to BRPI0413426-5A priority patent/BRPI0413426A/en
Priority to AU2004264405A priority patent/AU2004264405A1/en
Priority to US10/567,381 priority patent/US20080274112A1/en
Priority to PL380274A priority patent/PL380274A1/en
Priority to YUP-2006/0089A priority patent/RS20060089A/en
Priority to CA002535007A priority patent/CA2535007A1/en
Priority to JP2006522535A priority patent/JP2007501612A/en
Priority to EA200600376A priority patent/EA008253B1/en
Priority to EP04707073A priority patent/EP1660517A4/en
Publication of WO2004014311A2 publication Critical patent/WO2004014311A2/en
Publication of WO2004014311A3 publication Critical patent/WO2004014311A3/en
Priority to IS7677A priority patent/IS7677A/en
Priority to IL16665905A priority patent/IL166659A0/en
Priority to NO20050685A priority patent/NO20050685L/en
Priority to US11/055,163 priority patent/US7465705B2/en
Priority to IL173559A priority patent/IL173559A0/en
Priority to ZA200601909A priority patent/ZA200601909B/en
Priority to NO20061081A priority patent/NO20061081L/en
Priority to IS8339A priority patent/IS8339A/en
Priority to US12/335,328 priority patent/US8030456B2/en
Priority to JP2010106824A priority patent/JP2010207239A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)

Abstract

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen­binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.
PCT/US2003/025004 2002-08-10 2003-08-07 Nogo receptor antagonists WO2004014311A2 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
BRPI0313331-1A BR0313331A (en) 2002-08-10 2003-08-07 nogo receptor antagonists
DK03785123.5T DK1534736T3 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
EA200500330A EA200500330A1 (en) 2002-08-10 2003-08-07 ANTAGONISTS NOGO RECEPTORS
DE60332842T DE60332842D1 (en) 2002-08-10 2003-08-07 ANTAGONISTS OF NOGO RECEPTOR
SI200331860T SI1534736T1 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
CA002495121A CA2495121A1 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
EP03785123A EP1534736B1 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
MXPA05001615A MXPA05001615A (en) 2002-08-10 2003-08-07 Nogo receptor antagonists.
AU2003264033A AU2003264033A1 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
YUP-2005/0129A RS20050129A (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
AT03785123T ATE469913T1 (en) 2002-08-10 2003-08-07 ANTAGONISTS OF THE NOGO RECEPTOR
JP2004527960A JP2005535329A (en) 2002-08-10 2003-08-07 NOGO receptor antagonist
US10/567,381 US20080274112A1 (en) 2003-08-07 2004-01-30 Nogo Receptor Antagonists
EP04707073A EP1660517A4 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists
MXPA06001444A MXPA06001444A (en) 2003-08-07 2004-01-30 Nogo receptor antagonists.
BRPI0413426-5A BRPI0413426A (en) 2003-08-07 2004-01-30 new receptor antagonists
AU2004264405A AU2004264405A1 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists
PCT/US2004/002702 WO2005016955A2 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists
PL380274A PL380274A1 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists
YUP-2006/0089A RS20060089A (en) 2002-08-10 2004-01-30 Nogo receptor antagonists
CA002535007A CA2535007A1 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists
JP2006522535A JP2007501612A (en) 2003-08-07 2004-01-30 Nogo receptor antagonist
EA200600376A EA008253B1 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists
CNA2004800294122A CN1926147A (en) 2003-08-07 2004-01-30 NOGO receptor antagonists
IS7677A IS7677A (en) 2002-08-10 2005-01-28 Antagonist Nogo receptors
IL16665905A IL166659A0 (en) 2002-08-10 2005-02-02 Nogo receptor antagonists
NO20050685A NO20050685L (en) 2002-08-10 2005-02-09 NOGO receptor antagonists
US11/055,163 US7465705B2 (en) 2002-08-10 2005-02-10 Nogo receptor antagonists
IL173559A IL173559A0 (en) 2002-08-10 2006-02-06 Nogo receptor antagonists
ZA200601909A ZA200601909B (en) 2002-08-10 2006-03-06 Nogo receptor antagonists
NO20061081A NO20061081L (en) 2003-08-07 2006-03-06 Nogo reseptorentagonister
IS8339A IS8339A (en) 2003-08-07 2006-03-07 Anti-NOGO receptor antagonists
US12/335,328 US8030456B2 (en) 2002-08-10 2008-12-15 Nogo receptor antagonists
JP2010106824A JP2010207239A (en) 2002-08-10 2010-05-06 Nogo RECEPTOR ANTAGONIST

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40286602P 2002-08-10 2002-08-10
US60/402,866 2002-08-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/055,163 Continuation US7465705B2 (en) 2002-08-10 2005-02-10 Nogo receptor antagonists

Publications (2)

Publication Number Publication Date
WO2004014311A2 WO2004014311A2 (en) 2004-02-19
WO2004014311A3 true WO2004014311A3 (en) 2004-04-29

Family

ID=31715907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025004 WO2004014311A2 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists

Country Status (21)

Country Link
US (2) US7465705B2 (en)
JP (3) JP2005535329A (en)
KR (1) KR20050062525A (en)
CN (1) CN1681838A (en)
AT (1) ATE469913T1 (en)
AU (1) AU2003264033A1 (en)
BR (1) BR0313331A (en)
CA (1) CA2495121A1 (en)
DE (1) DE60332842D1 (en)
DK (1) DK1534736T3 (en)
EA (1) EA200500330A1 (en)
ES (1) ES2346868T3 (en)
IL (2) IL166659A0 (en)
IS (1) IS7677A (en)
MX (1) MXPA05001615A (en)
NO (1) NO20050685L (en)
PL (1) PL375301A1 (en)
PT (1) PT1534736E (en)
RS (2) RS20050129A (en)
WO (1) WO2004014311A2 (en)
ZA (2) ZA200501135B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
DK1325130T3 (en) * 2000-10-06 2010-05-25 Univ Yale Nogo Receptor Homologs
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
ATE469913T1 (en) 2002-08-10 2010-06-15 Univ Yale ANTAGONISTS OF THE NOGO RECEPTOR
AU2003265561A1 (en) * 2002-08-15 2004-03-03 Acorda Therapeutics, Inc. Chimeric protein
US20070065429A1 (en) * 2003-04-16 2007-03-22 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA05012305A (en) * 2003-05-16 2006-04-18 Acorda Therapeutics Inc Compositions and methods for the treatment of cns injuries.
MXPA05012307A (en) * 2003-05-16 2006-07-03 Acorda Therapeutics Inc Proteoglycan degrading mutants for treatment of cns.
EA008253B1 (en) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Nogo receptor antagonists
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
BRPI0507272A (en) * 2004-01-30 2007-06-26 Biogen Idec Inc treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
AU2005244933B2 (en) 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
ES2395094T3 (en) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Treatment of conditions that involve demyelination
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
EP1805209A4 (en) * 2004-10-01 2008-04-02 Univ Yale Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
MX2008000253A (en) 2005-07-08 2008-04-02 Biogen Idec Inc Sp35 antibodies and uses thereof.
WO2007025219A2 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof
EP1928490B8 (en) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
JPWO2007074747A1 (en) * 2005-12-26 2009-06-04 株式会社クラレ Cell culture materials
CN103215293B (en) * 2006-01-27 2015-10-28 比奥根Ma公司 NOGO receptor antagonist
US20110123535A1 (en) * 2006-05-15 2011-05-26 Biogen Idec Ma Inc. Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
WO2008027526A1 (en) * 2006-08-31 2008-03-06 Biogen Idec Ma Inc. Methods relating to peripheral administration of nogo receptor polypeptides
AU2007299738B2 (en) 2006-09-20 2013-03-28 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
CA2670368C (en) * 2006-11-21 2018-05-29 Abbott Laboratories Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
WO2009070957A1 (en) * 2007-12-05 2009-06-11 Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences Inhibitor of the interaction between blys and ngr and use thereof
EP3581169A1 (en) 2008-01-22 2019-12-18 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US8992918B2 (en) 2008-03-13 2015-03-31 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
DK2982695T3 (en) 2008-07-09 2019-05-13 Biogen Ma Inc COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF
JP2011527317A (en) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Treatment of amyotrophic lateral sclerosis with NOGO-A antagonist
US20110020359A1 (en) * 2009-07-24 2011-01-27 California Institute Of Technology Methods and compositions for treating neuronal damage or degeneration
JP6268164B2 (en) 2012-04-09 2018-01-24 ケース ウエスタン リザーブ ユニバーシティ Compositions and methods for inhibiting the activity of LAR family phosphatases
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
KR101685109B1 (en) * 2014-12-22 2016-12-09 경북대학교 산학협력단 A use of Nogo-A related to differentiation, regeneration, or disease condition of muscle
MX2017009038A (en) 2015-01-08 2017-10-25 Biogen Ma Inc Lingo-1 antagonists and uses for treatment of demyelinating disorders.
CN113527462B (en) * 2020-04-22 2023-05-23 北京大学 Small molecule peptide with analgesic effect and specific antibody thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
DE69233750D1 (en) 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
CA2347835A1 (en) 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
BR0107613A (en) 2000-01-12 2002-11-19 Univ Yale Blockade of axon growth mediated by nogo receptor
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DK1325130T3 (en) 2000-10-06 2010-05-25 Univ Yale Nogo Receptor Homologs
AU2002331180A1 (en) 2001-08-27 2003-03-10 Novartis Pharma Gmbh Nogo receptor homologues and their use
JP2005519584A (en) 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト NOGO receptor homologues and their use
US7309485B2 (en) 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US20030113325A1 (en) 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
EP1354892A1 (en) 2002-04-19 2003-10-22 Centre National De La Recherche Scientifique (Cnrs) Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases
US7745151B2 (en) 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
ATE469913T1 (en) 2002-08-10 2010-06-15 Univ Yale ANTAGONISTS OF THE NOGO RECEPTOR
US20070065429A1 (en) 2003-04-16 2007-03-22 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
PL380274A1 (en) 2003-08-07 2007-01-22 Biogen Idec Ma Inc. Nogo receptor antagonists
EA008253B1 (en) 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Nogo receptor antagonists
BRPI0507272A (en) * 2004-01-30 2007-06-26 Biogen Idec Inc treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
WO2008027526A1 (en) 2006-08-31 2008-03-06 Biogen Idec Ma Inc. Methods relating to peripheral administration of nogo receptor polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OERTLE T. ET AL.: "Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions", J. NEUROSCI., vol. 23, no. 13, 2 July 2003 (2003-07-02), pages 5393 - 5406, XP002973436 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein

Also Published As

Publication number Publication date
ES2346868T3 (en) 2010-10-21
JP2005535329A (en) 2005-11-24
AU2003264033A1 (en) 2004-02-25
US20090215691A1 (en) 2009-08-27
US8030456B2 (en) 2011-10-04
IS7677A (en) 2005-01-28
RS20060089A (en) 2008-08-07
IL166659A0 (en) 2006-01-15
ZA200501135B (en) 2006-10-25
WO2004014311A2 (en) 2004-02-19
US7465705B2 (en) 2008-12-16
CA2495121A1 (en) 2004-02-19
NO20050685L (en) 2005-05-10
JP2010207239A (en) 2010-09-24
PT1534736E (en) 2010-09-07
MXPA05001615A (en) 2005-08-19
ATE469913T1 (en) 2010-06-15
DE60332842D1 (en) 2010-07-15
BR0313331A (en) 2007-07-24
JP2011173899A (en) 2011-09-08
KR20050062525A (en) 2005-06-23
US20050271655A1 (en) 2005-12-08
PL375301A1 (en) 2005-11-28
ZA200601909B (en) 2007-05-30
IL173559A0 (en) 2006-07-05
RS20050129A (en) 2007-06-04
CN1681838A (en) 2005-10-12
EA200500330A1 (en) 2006-06-30
DK1534736T3 (en) 2010-09-20

Similar Documents

Publication Publication Date Title
WO2004014311A3 (en) Nogo receptor antagonists
IS8339A (en) Anti-NOGO receptor antagonists
WO2007089601A3 (en) Nogo receptor antagonists
HK1211618A1 (en) Nogo receptor binding protein nogo
WO2000018932A3 (en) Receptor based antagonists and methods of making and using
WO2004039951A3 (en) Il-1 receptor based antagonists and methods of making and using
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
EA200600376A1 (en) ANTAGONISTS OF NOGO RECEPTOR

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0129

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 166659

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020057002176

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2495121

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005/01135

Country of ref document: ZA

Ref document number: 200501135

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004527960

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 375301

Country of ref document: PL

Ref document number: PA/a/2005/001615

Country of ref document: MX

Ref document number: 11055163

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003264033

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 538648

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 382/KOLNP/2005

Country of ref document: IN

Ref document number: 20038214091

Country of ref document: CN

Ref document number: 200500330

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2003785123

Country of ref document: EP

Ref document number: 8680

Country of ref document: GE

WWP Wipo information: published in national office

Ref document number: 2003785123

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057002176

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500279

Country of ref document: PH

ENP Entry into the national phase

Ref document number: PI0313331

Country of ref document: BR